Andere talen Seegene, Inc.

Aandelen

A096530

KR7096530001

slotkoers Korea S.E. Andere beurzen 00:00:00 17-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
21.000 ^KRW	0,00%		-6,67%	-8,30%

14/03	Seegene, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
24/01	Seegene Inc. Kondigt samenwerking met Microsoft aan om een wereld vrij van alle ziekten te realiseren	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Seegene and UK Health Security Agency convene a summit to collectively realize 'a World Free from All Diseases'	09/04
Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"	08/04
Seegene and Springer Nature Announce Awardees for the Open Innovation Program	15/03
Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Seegene Announces Collaboration with Microsoft to Realize 'a World Free from All Diseases'	24/01
Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases	24/01
Seegene obtains ISO45001 certification	27/12
Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy; Expanded Collaboration Aims To Improve Syndromic Infectious Disease Testing	14/12
Microbix Brief: Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy	14/12
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Seegene Earns Improved ESG Rating from the Korea Institute of Corporate Governance and Sustainability	10/11
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on July 13, 2023.	13-10-23
Seegene Unveils 'Open Innovation Program Powered by Seegene' in Partnership with Springer Nature	04-09-23
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023.	28-08-23
Seegene, Inc.'s Equity Buyback announced on February 28, 2023, has expired with 2,046,354 shares, representing 4.11% for KRW 49,998.4 million.	28-08-23
Seegene, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14-08-23
Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC	31-07-23
Seegene, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares.	13-07-23
Seegene, Inc. authorizes a Buyback Plan.	13-07-23
Seegene, Inc. and Werfen Partner to Collaborate on Onesystem Business to Develop Syndromic qPCR Assays	14-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Seegene, Inc.

Aandelen

A096530

KR7096530001

Andere talen

Filters